Tirzepatide vs semaglutide dose: what a comparison can mean
Amounts alone do not rank different medicines. A fair comparison starts with the outcome and the people in the same trial.

Appetite and blood sugar share a starting point
Tirzepatide activates receptors, the cell's receiving points, for gut-hormone signals called GIP and GLP-1. Semaglutide activates GLP-1 receptors. These actions help explain blood-sugar effects. GLP-1 also regulates appetite. Evidence that GIP adds to food-intake regulation is partly from animal studies, so counting receptors can't explain a person's result.
Two direct trials are more useful here. One studied blood sugar in adults with type 2 diabetes. The other studied weight in adults with obesity without type 2 diabetes. Keeping those groups separate saves a lot of confusion.
For blood sugar
Tirzepatide
In the 40-week SURPASS-2 diabetes trial, tirzepatide reduced HbA1c more than the semaglutide dose tested in adults with type 2 diabetes. HbA1c is a blood test that reflects average blood sugar over recent months; it isn't a single blood-sugar reading.
SURPASS-2 compared several tirzepatide study groups with one semaglutide group under a supervised research plan. The groups were defined in advance; the findings do not create an exchange rate between the medicines.
Semaglutide
The semaglutide group in the same SURPASS-2 trial received one particular study strength. That detail matters: the study did not compare tirzepatide with every semaglutide strength or form.
Participants knew their assigned medicine: this was an open-label trial. The result supports this particular comparison, rather than a blanket claim that one ingredient is better for everything.
For body weight
Tirzepatide
In the direct obesity trial, the estimated average weight loss with tirzepatide was 20.2% of starting weight at 72 weeks. The trial, SURMOUNT-5, enrolled adults with obesity without type 2 diabetes.
Lilly, the maker of tirzepatide, funded it. It was open-label: participants and researchers knew the assigned treatment.
Semaglutide
In that same trial, the estimated average weight loss with semaglutide was 13.7%. Both medicines were studied as weekly injections at the maximum tolerated doses within the trial's plan. These percentages are the study's statistical estimates of average changes, not results every participant had.
Tirzepatide had the larger average reduction. The trial didn't test every semaglutide product, and an average doesn't predict your result.
What remains outside those results
Neither trial picks a medicine for you. Other health goals, side effects and medical history still matter. Nor do these trials establish that a compounded preparation will give the same results; compounded medicines aren't FDA-approved.
Leave room for the warnings
The tirzepatide and semaglutide labels both list nausea, vomiting, diarrhea and constipation. They also warn about pancreatitis, or inflammation of the pancreas, and gallbladder problems.
Both have the FDA's strongest label warnings, called boxed warnings, about thyroid C-cell tumors seen in rodents, with human relevance unknown. Reasons the labels rule out use include a personal or family history of medullary thyroid cancer, or having MEN 2, an inherited condition. Those warnings belong in the conversation alongside the results.
The product remains part of the question
A direct trial can support a comparison without deciding what belongs in a particular prescription. The reason for treatment, other medicines, medical history, and the exact preparation remain individual matters.
The dosage discussion separates amounts, concentration, and supervised study plans. There is no conversion chart here: a numerical ratio between the ingredients would leave out how each medicine behaves and how the study treatments were chosen.
The two trial questions cannot be exchanged
A weight outcome and a blood-sugar outcome may both improve without describing the same benefit. HbA1c reflects average blood sugar over recent months. Weight is a different measurement, and neither measure directly records strength, comfort, or the demands of an ordinary day.
The direct obesity trial also does not answer which preparation preserves more muscle. The body-composition discussion comes from a separate substudy without a semaglutide group. Reading it beside the comparison is useful, but joining the papers cannot create a result that neither study measured.